Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — FY2017 Earnings Presentation
17 slides from Vita Life Sciences's earnings presentation, Feb 22, 2018
Slide 1: Results Presentation Full Year Ended 31 Dec 2017
RESULTS PRESENTATION For personal use only FULL YEAR ENDED 31 DEC 2017 22 Feb 2018
Slide 2: Vita Life Sciences Overview
VITA LIFE SCIENCES OVERVIEW For personal use only • Australian & Asia Pacific based pharmaceutical and healthcare over-the-counter business involved in the formulating, packaging, sales and distribution of vitamins and supplements • 3 major consumer retail brands • 750-800 registered SKUs of vitamin
Slide 3: FY 2017 - Group Summary
FY 2017 - GROUP SUMMARY For personal use only • Group sales of $37.7 million for the financial year (FY) ended Dec 2017, marginally lower (0.2%) than the previous corresponding period (PCP) of $37.8 million • Excluding share options expense of $0.9m, the Group recorded an EBIT of $5.6m (i.e. $4.7m a
Slide 4: Key Financial Charts
Key Financial Charts For personal use only Revenue EBIT* EPS* (A$m) (cps) (A$m) 40 6 7 35 6 30 4 5 25 4 20 3 6.06 15 2 4.89 10 2 5 1 0 0 0 2017 2016 2017 2016 2017 2016 * Including share options expense of $0.9m
Slide 5: Full Year 2017 Results: Revenue by Geography
FULL YEAR 2017 RESULTS For personal use only 2017 revenue by geography 2016 revenue by geography Other Asia Australia Other Australia 7% 41% Asia 41% 6% Singapore 17% Singapore 17% Asia Asia 59% 59% Malaysia Malaysia 36% 35% Total revenue: $37.7m Total revenue: $37.8m
Slide 6: Segment Results: Australia
SEGMENT RESULTS Revenue (A$m) AUSTRALIA 16.0 For personal use only 12.0 H2 H2 8.0 Sales revenue: $15.6m (2016: $15.6m) Revenue base business was sustained in a highly 4.0 H1 H1 competitive Australian market. - Export sales from Australia to China were slower 2017 2016 than expected EBIT (A$m)
Slide 7: Segment Results: Malaysia
Revenue (A$m) SEGMENT RESULTS 16 MALAYSIA 12 For personal use only H2 H2 8 4 Sales $13.2m (2016: $13.5m) H1 H1 Revenue base increased by 6.7% in local currency but it was impacted by the 0 weaker Malaysian ringgit (2017 average A$1: MYR 3.2971 [2016: MYR 3.0072]) 2017 2016 EBIT (A$m) Increase in
Slide 8: Segment Results: Singapore
Revenue (A$m) SEGMENT RESULTS SINGAPORE 6 For personal use only H2 H2 4 2 H1 H1 Sales $6.5m (2016: $6.5m) Revenue base business was sustained in a highly competitive 0 market through a revised brand strategy. 2017 2016 The Herbs of Gold brand recorded strong growth of 119% EBIT (A$m) (PCP) Vit
Slide 9: Segment Results: Others
SEGMENT RESULTS OTHERS For personal use only Revenue (A$m) Sales $2.5m (2016: $2.2m) Revenue in other markets growth of 15% (PCP) 2 Stronger sales were recorded for Vietnam and Thailand H2 H2 compared to the PCP Vietnam continues to perform to expectation and is expected to grow faster leading
Slide 10: Final Dividend & Cashflow
FINAL DIVIDEND & CASHFLOW For personal use only • Final dividend declared of 2.25 cents per share for FY 2017 (2016: 2.25 cents) • Final dividend will be fully franked. Directors anticipate future dividends to be fully franked. • Dividend reinvestment plan is currently suspended Gross operating Divi
Slide 11: Strategic Priorities and Outlook
Strategic Priorities and Outlook For personal use only • 2018 will be the second year of a three year strategic plan set to grow future revenues • Increased advertising and promotional investment in core markets • Increasing export sales to China utilising strategic partnerships • Developing new dis
Slide 12: Appendix
For personal use only APPENDIX
Slide 13: Appendix – Profit & Loss
APPENDIX 1 – PROFIT & LOSS For personal use only Full year ended Dec 2017 2016 $m $m Revenue 37.7 37.8 EBITDA 5.0 6.0 EBIT 4.7 5.7 Profit before tax 4.7 5.6 Profit after tax 2.8 3.3 EPS (Basic – cents/ share) 5.21 6.06 Dividend (cents / share) 3.75 3.75
Slide 14: Appendix – Balance Sheet
APPENDIX 2 – BALANCE SHEET For personal use only Balance Sheet as at Dec 2017 Dec 2016 $m $m Current assets 22.3 21.7 Non-current assets 10.6 10.6 Total assets 32.9 32.3 Current liabilities 6.0 6.8 Non-current liabilities 2.1 2.3 Total Liabilities 8.1 9.1 Net Assets 24.8 23.2
Slide 15: Appendix – Cash Flow
APPENDIX 3 – CASH FLOW For personal use only Cash Flow for the year ended 2017 2016 $m $m Receipts from customers 40.8 41.6 Payments to suppliers and employees 34.8 36.2 Gross operating cash flow 6.0 5.4 Adjusted EBITDA (excluding share options expense) 6.0 6.0 Gross operating cash flow / EBITDA 100
Slide 16: Contact
CONTACT For personal use only Telephone: +61 2 9545 2633 Website: vitalifesciences.com Email: enquiries@vitalifesciences.com Head Office: 1/102 Bath Road, Kirrawee, NSW 2232
Slide 17: Disclaimer
DISCLAIMER For personal use only This document has been prepared by Vita Life Sciences Limited (Vita Life Sciences) and comprises written material/slides for a presentation concerning Vita Life Sciences. The presentation is for information purposes only and does not constitute or form part of any of